Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
Clinical trial NCT00216593 · COMPLETED
Trial details
- NCT number
- NCT00216593
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2003-12-01
- Primary completion
- 2007-09-01
- Enrollment
- 415
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.